Target Ophthalmic Clinics Small to mid sized ophthalmology clinics and retina specialists using non-invasive retinal imaging represent a core opportunity for Vasoptic’s XyCAM RI. Leverage FDA clearance and portable design to target clinics upgrading diagnostic capabilities and seeking cost-effective imaging solutions.

Healthcare Grants & Foundations Past funding from the Abell Foundation and federal grants indicate availability of non-dilutive sources and potential partnerships. Develop strategies to align product development milestones with grant opportunities and foundation-sponsored pilot programs.

Mid-Market Expansion With revenue in the sub-10 million range and a nimble team, Vasoptic can pursue mid-market health systems and group practices that need scalable retinal blood flow imaging. Emphasize total cost of ownership, portability, and rapid deployment.

Non-Invasive Advantage Position XyCAM RI as a non-invasive, dynamic vascular assessment tool that complements existing ophthalmic workflows. Highlight potential to aid early diagnosis of systemic and ocular conditions to broaden use in clinics and diagnostic centers.

Strategic Partnerships Explore collaborations with larger ophthalmology device firms or distributors to accelerate reach. Use success signals from comparable peers to pitch co-marketing, training programs, and bundled offerings to accelerate adoption.